COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

被引：0
|
作者：
Vazquez, M. [1 ]
Canete, J. D. [2 ]
Nicolas, J. [3 ]
Peral, C. [4 ]
Gomez, S. [4 ]
Lopez, A. [4 ]
Prades, M. [5 ]
Rebollo, F. [4 ]
机构：
[1] Hosp Ramon & Cajal, Rheumatol Dept, Madrid, Spain
[2] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain
[3] Hosital Univ Mutua Terrassa, Pharm Dept, Terrassa, Spain
[4] Pfizer SLU, Madrid, Spain
[5] Outcomes10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY16
引用
收藏
页码：S904 / S904
页数：1
相关论文
共 50 条
  • [31] An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis
    So, Anthony
    Inman, Robert Davies
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (03): : 453 - 471
  • [32] The Actual Role of Therapy with Traditional Disease-modifying Antirheumatic Drugs in Psoriatic Arthritis
    Soriano, Enrique R.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 : 67 - 70
  • [33] Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis
    Syngle, Ashit
    Verma, Inderjeet
    Krishan, Pawan
    Syngle, Vijaita
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2016, 8 (02) : 42 - 48
  • [34] Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand
    Dilokthornsakul, Piyameth
    Sawangjit, Ratree
    Osiri, Manathip
    Chiowchanwisawakit, Praveena
    Louthrenoo, Worawit
    Permsuwan, Unchalee
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 40 - 47
  • [35] Disease-modifying antirheumatic drug therapy for psoriatic arthritis
    Salvarani, C
    Cantini, F
    Olivieri, I
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (06) : S71 - S75
  • [36] Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
    Michael T. Nurmohamed
    Ben A. C. Dijkmans
    Drugs, 2005, 65 : 661 - 694
  • [37] COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) COMPARED TO STANDARD OF CARE IN SINGAPORE
    Chua, J. N.
    Lahiri, M.
    Cheung, P. P.
    Yoong, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 834 - 835
  • [38] Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Hosseini, Roya
    Brown, Lawrence
    Fleming, Marc
    Rodriguez-Monguio, Rosa
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2161 - 2162
  • [39] Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis
    Nurmohamed, MT
    Dijkmans, BAC
    DRUGS, 2005, 65 (05) : 661 - 694
  • [40] Cost-Effectiveness of Biologics in Polyarticular-Course Juvenile Idiopathic Arthritis Patients Unresponsive to Disease-Modifying Antirheumatic Drugs
    Ungar, Wendy J.
    Costa, Vania
    Hancock-Howard, Rebecca
    Feldman, Brian M.
    Laxer, Ronald M.
    ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 111 - 119
12345